Reference : Prevention du diabete de type 2: style de vie ou medicaments?
Scientific journals : Article
Human health sciences : Endocrinology, metabolism & nutrition
http://hdl.handle.net/2268/12490
Prevention du diabete de type 2: style de vie ou medicaments?
French
[en] Prevention of type 2 diabetes: lifestyle changes or pharmacological interventions?
Scheen, André mailto [Université de Liège - ULg > Département des sciences cliniques > Diabétologie, nutrition et maladie métaboliques - Médecine interne générale >]
Letiexhe, Michel [Centre Hospitalier Universitaire de Liège - CHU > > Diabétologie,nutrition, maladies métaboliques >]
Ernest, Philippe mailto [Centre Hospitalier Universitaire de Liège - CHU > > Diabétologie,nutrition, maladies métaboliques >]
2003
Revue Médicale de Liège
58
4
206-10
Yes (verified by ORBi)
0370-629X
Belgium
[en] Angiotensin-Converting Enzyme Inhibitors/therapeutic use ; Diabetes Mellitus, Type 2/prevention & control ; Enzyme Inhibitors/therapeutic use ; Health Behavior ; Humans ; Hypoglycemic Agents/therapeutic use ; Lactones/therapeutic use ; Life Style
[en] The World Health Organisation strongly recommends strategies for the prevention of type 2 diabetes, knowing the epidemics of the disease and its strong association with that of obesity. Several intervention studies, in China ("Da-Qing Study"), in Europe ("Malmo study", "Finnish Diabetes Prevention Study") and in the United States ("Diabetes Prevention Program"), showed that lifestyle change are able to reduce by around 50% the incidence of type 2 diabetes in at risk individuals. Various pharmacological approaches have also proven their efficacy in preventing type 2 diabetes, but in most cases with less impressive reductions, between 25% and 35%. It is the case for metformin, acarbose, orlistat or various inhibitors of the renin-angiotensin system. After the report of promising results with troglitazone, large prospective studies are ongoing to test the efficacy of rosiglitazone and pioglitazone in such an indication, two insulinsensitizers of the thiazolidinedione family. We will briefly described the main results of intervention studies to prevent type 2 diabetes in at risk subjects, because of the presence of obesity, impaired glucose tolerance and/or arterial hypertension.
Researchers ; Professionals ; Students
http://hdl.handle.net/2268/12490
http://www.rmlg.ulg.ac.be

File(s) associated to this reference

Fulltext file(s):

FileCommentaryVersionSizeAccess
Open access
200304_06.pdfNo commentaryPublisher postprint447.03 kBView/Open

Bookmark and Share SFX Query

All documents in ORBi are protected by a user license.